However, SMARCA4 mutations can occur in approximately 5–16% of primary lung cancers (Orvis et al., 2014; Reisman et al., 2003) and in approximately 10–15% of lung adenocarcinomas (Reisman et al., 2003; Hoffman et al., 2014). Here, SMARCA4 is linked to lung adenocarcinoma.